A091102: Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma. This study is for patients who have a soft tissue sarcoma that has spread or recurred.


The purpose of this study is to see the effects, good and/or bad, of MLN8237 on patients with sarcoma. The goal of this study is to see if there is any effect of this drug in treating sarcoma.

MLN8237 is a new investigational drug currently being tested for treatment of sarcoma. Cancer research has shown that there are many proteins within cancer that cause it to grow continuously. Aurora kinase is one of those proteins. MLN8237 is a pill that blocks the activity of Aurora kinase. All subjects will take MLN8237 pills by mouth twice a day for 7 days and then take no pills for 14 days. This cycle will be repated as long as the sarcoma is not getting worse and side effects are tolerable.


A091103: Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma


This study is for patients who have been diagnosed with angiosarcoma that is unable to be removed by surgery.

The purpose of this study is to find out what effects, good and/or bad, an experimental drug called AMG 386 has on angiosarcoma. This drug works by blocking proteins known as angiopoietins. Angiopoietins are proteins that have the effect of causing cancer to grow by increasing the growth of blood vessels in a tumor. In laboratory testing, AMG 386 has been shown to block the effects of angiopoietins on tumor growth. Laboratory testing has also indicated that angiopoietins may be important in the growth of angiosarcoma. This drug has also been shown to have some effectiveness in other cancers but has not been evaluated yet in angiosarcoma.

All subjects will receive an intravenous infusion (through a needle into a vein) of AMG 386 given over about one hour once a week until the cancer gets worse or side effects are intolerable.

Additional information on this study from ClinicalTrials.gov